Optometry. 2004 Apr;75(4):216-30. Related Articles, Links
Double-masked, placebo-controlled, randomized trial of
lutein and antioxidant supplementation in the intervention
of atrophic age-related macular degeneration: the Veterans
LAST study (Lutein Antioxidant Supplementation Trial).
Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy
D, Pei K, Tsipursky M, Nyland J.
Department of Veterans'Affairs, Medical Center Eye Clinic,
North Chicago, Illinois 60064-3095, USA.
[email hidden]
BACKGROUND: Age-related macular degeneration (ARMD) is the
leading cause of vision loss in aging Westem societies. The
objective of the lutein antioxidant supplementation trial
(LAST) is to determine whether nutritional supplementation
with lutein or lutein together with antioxidants, vitamins,
and minerals, improves visual function and symptoms in
atrophic ARMD. METHODS: The study was a prospective, 12-
month, randomized, double-masked, placebo-controlled trial
conducted at an urban midwestern Veterans Administration
Hospital from August 1999 to May 2001. Ninety patients with
atrophic ARMD were referred by ophthalmologists at two Chicago-
area veterans medical facilities. Patients in Group 1
received lutein 10 mg (L); in Group 2, a lutein 10
mg/antioxidants/vitamins and minerals broad spectrum
supplementation formula (L/A); and in Group 3, a
maltodextrin placebo (P) over 12 months. RESULTS: In Groups
1 L and 2 L/A, mean eye macular pigment optical density
increased approximately 0.09 log units from baseline,
Snellen equivalent visual acuity improved 5.4 letters for
Group 1 L and 3.5 letters for Group 2 L/A, and contrast
sensitivity improved. There was a net subjective improvement
in Amsler grid in Group 1 L. VFO-14 questionnaires conceming
subjective glare recovery were nearly significant at 4
months for Group 2 L/A. Patients who received the placebo
(Group 3) had no significant changes in any of the measured
findings. CONCLUSION: In this study, visual function is
improved with lutein alone or lutein together with other
nutrients. Further studies are needed with more patients, of
both genders, and for longer periods of time to assess long-
term effects of lutein or lutein together with a broad
spectrum of antioxidants, vitamins, and minerals in the
treatment of atrophic age-related macular degeneration.
BACKGROUND: Age-related macular degeneration (ARMD) is the
leading cause of vision loss in aging Western societies. The
objective of the lutein antioxidant supplementation trial
(LAST) is to determine whether nutritional supplementation
with lutein or lutein together with antioxidants, vitamins,
and minerals, improves visual function and symptoms in
atrophic ARMD. METHODS: The study was a prospective, 12-
month, randomized, double-masked, placebo-controlled trial
conducted at an urban midwestern Veterans Administration
Hospital from August 1999 to May 2001. Ninety patients with
atrophic ARMD were referred by ophthalmologists at two Chicago-
area veterans medical facilities. Patients in Group 1
received lutein 10 mg (L); in Group 2, a lutein 10
mg/antioxidants/vitamins and minerals broad spectrum
supplementation formula (L/A); and in Group 3, a
maltodextrin placebo
(P) over 12 months. RESULTS: In Groups 1 L and 2 L/A, mean
eye macular pigment optical density increased
approximately 0.09 log units from baseline, Snellen
equivalent visual acuity improved 5.4 letters for Group
1 L and 3.5 letters for Group 2 L/A, and contrast
sensitivity improved. There was a net subjective
improvement in Amsler grid in Group 1 L VFQ-14
questionnaires concerning subjective glare recovery were
nearly significant at 4 months for Group 2 L/A. Patients
who received the placebo (Group 3) had no significant
changes in any of the measured findings. CONCLUSION: In
this study, visual function is improved with lutein
alone or lutein together with other nutrients. Further
studies are needed with more patients, of both genders,
and for longer periods of time to assess long-term
effects of lutein or lutein together with a broad
spectrum of antioxidants, vitamins, and minerals in the
treatment of atrophic age-related macular degeneration.
PMID: 15117055 [PubMed - in process]
------------------------------------------------------------
--------------
------
Who loves ya. Tom Jesus Was A Vegetarian!
jesuswasavegetarian.7h.comjesuswasavegetarian.7h.comOpen ↗ Man Is A Herbivore!
pages.ivillage.commanisaherbivoreOpen ↗ DEAD
PEOPLE WALKING
pages.ivillage.comdeadpeoplewalkingOpen ↗